Cargando…

Bisphosphonates as antimyeloma drugs

In patients with symptomatic multiple myeloma (MM), bisphosphonate (BP) treatment has been widely used to prevent bone loss and preserve skeletal health because of its proven effects on inhibiting osteoclast-mediated bone resorption. In addition to their effects on osteoclasts, it is becoming increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, N D, Lentzsch, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364444/
https://www.ncbi.nlm.nih.gov/pubmed/22005788
http://dx.doi.org/10.1038/leu.2011.282
_version_ 1782234537510567936
author Modi, N D
Lentzsch, S
author_facet Modi, N D
Lentzsch, S
author_sort Modi, N D
collection PubMed
description In patients with symptomatic multiple myeloma (MM), bisphosphonate (BP) treatment has been widely used to prevent bone loss and preserve skeletal health because of its proven effects on inhibiting osteoclast-mediated bone resorption. In addition to their effects on osteoclasts, it is becoming increasingly evident that BPs may have additional effects on the bone microenvironment and cells other than osteoclasts that may potentially inhibit the development and progression of MM. This review focuses on the pathophysiology of MM with an emphasis on the events that drive MM progression within the bone and the mechanisms by which BPs may inhibit specific processes. The underlying molecular mechanisms that drive the modulation of cellular fate and function and consequent physiological outcomes are described. Direct effects on myeloma cell growth and survival and the interactions between myeloma cells and the bone microenvironment are discussed. Clinical evidence of the antimyeloma effects of BPs is emerging and is also reviewed.
format Online
Article
Text
id pubmed-3364444
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33644442012-05-31 Bisphosphonates as antimyeloma drugs Modi, N D Lentzsch, S Leukemia Review In patients with symptomatic multiple myeloma (MM), bisphosphonate (BP) treatment has been widely used to prevent bone loss and preserve skeletal health because of its proven effects on inhibiting osteoclast-mediated bone resorption. In addition to their effects on osteoclasts, it is becoming increasingly evident that BPs may have additional effects on the bone microenvironment and cells other than osteoclasts that may potentially inhibit the development and progression of MM. This review focuses on the pathophysiology of MM with an emphasis on the events that drive MM progression within the bone and the mechanisms by which BPs may inhibit specific processes. The underlying molecular mechanisms that drive the modulation of cellular fate and function and consequent physiological outcomes are described. Direct effects on myeloma cell growth and survival and the interactions between myeloma cells and the bone microenvironment are discussed. Clinical evidence of the antimyeloma effects of BPs is emerging and is also reviewed. Nature Publishing Group 2012-04 2011-10-18 /pmc/articles/PMC3364444/ /pubmed/22005788 http://dx.doi.org/10.1038/leu.2011.282 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Review
Modi, N D
Lentzsch, S
Bisphosphonates as antimyeloma drugs
title Bisphosphonates as antimyeloma drugs
title_full Bisphosphonates as antimyeloma drugs
title_fullStr Bisphosphonates as antimyeloma drugs
title_full_unstemmed Bisphosphonates as antimyeloma drugs
title_short Bisphosphonates as antimyeloma drugs
title_sort bisphosphonates as antimyeloma drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364444/
https://www.ncbi.nlm.nih.gov/pubmed/22005788
http://dx.doi.org/10.1038/leu.2011.282
work_keys_str_mv AT modind bisphosphonatesasantimyelomadrugs
AT lentzschs bisphosphonatesasantimyelomadrugs